Drugs / Spikevax
Spikevax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05075538 | Dec 2021 → Jan 2024 | cancer | Jules Bordet Institute | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT05160766 Comparator | Nov 2021 → Oct 2022 | — | Oliver Cornely, MD | Completed | No outcome recorded |
| Phase 2/3 | NCT05236491 Comparator | Mar 2022 → Jun 2023 | overlapping connective tissue disease, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis +2 | Paul R Fortin | Unknown | No outcome recorded |
| Phase 3 | NCT06354998 Comparator | Apr → May 2024 | Orthocoronavirinae infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05048940 Comparator | Sep 2021 | COVID-19 | Marqués de Valdecilla Research Institute (IDIVAL) | Withdrawn | No outcome recorded |
Press releases naming this drug 14 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spikevax | “For the Moderna SPIKEVAX Bivalent Original/Omicron BA.4/5: participants will receive one (1) intramuscular injection of 0.5 mL (50 mcg).” NCT05236491 ↗ |
| Known as | mRNA-1273 | “Spikevax (mRNA-1273)” NCT05160766 ↗ |
| Known as | SPIKEVAX Bivalent Original/Omicron BA.4/5 | “For the Moderna SPIKEVAX Bivalent Original/Omicron BA.4/5: participants will receive one (1) intramuscular injection of 0.5 mL (50 mcg).” NCT05236491 ↗ |
| Known as | Spikevax Moderna vaccine | “Spikevax (Moderna) vaccine” NCT05048940 ↗ |
| Modality | Vaccine | “vaccination with mRNA-1273 as 3rd vaccination” NCT05160766 ↗ |
| Route | Intramuscular | “0.5 ml millilitre(s) Intramuscular use” NCT05048940 ↗ |